Background: Dengue Virus (DENV) and Chikungunya Virus (CHIKV) pose significant public health threats in Brazil, where favorable conditions facilitated the proliferation of Aedes mosquitoes. Since the mid-1980s, Brazil has experienced annual outbreaks of DENV, with recent increases in confirmed cases. In addition, CHIKV, which was first reported in 2014, has spread across the country. The concurrent presence of these viruses has triggered public health alerts in endemic regions, underscoring the complexity of managing vector-borne diseases. Case presentation: This report details two cases of simultaneous DENV and CHIKV infections. A 77-year-old female patient with diabetes and arrhythmia exhibited symptoms including fever, myalgia, and severe arthralgia. Case #2 features a 12-year-old female with similar symptoms, showing positive RTPCR for both viruses. Laboratory tests confirmed the coinfection through RNA detection and serology. Patients received supportive care and showed gradual improvement, leading to a favorable outcome. Conclusion: Coinfection with DENV and CHIKV cases reported here developed with mild outcomes. However, one of the patients (Case#2) did not recover from the arthralgia after presenting diagnostic challenges, which underscores the need for accurate differentiation to manage symptoms effectively. The reported cases, amidst increasing DENV outbreaks, highlight the urgency for preparedness in the healthcare system. The Ribeirão Preto region’s endemicity of DENV and the rising incidence of CHIKV emphasizes the evolving landscape of arbovirus transmission. Studies on Aedes mosquitoes suggest potential implications for human infection dynamics, warranting further investigation into arbovirus transmission efficacy and coinfection dynamics.

• Dengue virus

• Chikungunya virus

• Co-infection

• Clinical studies

• Molecular characterization

• Phylogenetics

Torres PMA, de La-Roque DGL, Policastro LR, de Oliveira Chagas IBM, Giomo DB, et al. (2024) Simultaneous Dengue and Chikungunya Coinfection in Endemic Area in Brazil: Clinical Presentation and Implications for Public Health. JSM Clin Case Rep 12(2): 1236.

WBC: White Blood Cells; AST: Aspartate Aminotransferase; U/L: Units Per Liter; ALT: Alanine Aminotransferase; ND: Non Determined

Dengue Virus (DENV) and Chikungunya Virus (CHIKV) are arboviruses transmitted by the Aedes aegypti mosquito and belong to the Flavivirus and Alphaviruses genera, respectively [1,2]. As a tropical country, Brazil provides favorable conditions for the expansion and proliferation of Aedes mosquitoes. This condition allows these arboviruses to pose a significant threat to public health. Although Aedes mosquitoes were eradicated from Brazil in 1973, they returned in 1976-1977 due to their presence in neighboring countries [3]. They are now spread throughout the entire territory of Brazil, a phenomenon driven not only by the climate but also by population migration and intensive use of non-biodegradable materials [4].

DENV is classified into four serotypes

DENV-1 to DENV-4; each serotype is further divided into genotypes with up to a 6% genetic divergence [5]. The first outbreak in the Brazilian territory after the reemergence of Aedes mosquitoes was caused by DENV-1 genotype V in Rio de Janeiro, a state located in the southeast portion of Brazil [4,6]. Since then, Brazil has experienced annual outbreaks, continuing up to the present, with introductions of new serotypes and genotypes. In the first two months of 2024, the number of confirmed cases has been alarmingly high compared to previous years across several states. These data have triggered a public health alert in many regions of Brazil. For this reason, the Ministry of Health established an emergency committee to coordinate a nationwide response and assist symptomatic individuals.

Genetic variability of CHIKV classifies it into four distinct genotypes—West African, Asian, East/Central/South African (ECSA), and Indian Ocean Lineage [7]. In 2014, CHIKV was first reported in the northern region of Brazil, along the border with French Guiana. Since its introduction, CHIKV, while less prevalent than dengue, has had a significant impact on public health as it spread throughout the country [8,9]. Until 2017, the most prevalent Brazilian region was the Northeast, but since then, many cases have arisen, mainly in the Southeast region.

Ribeirão Preto is an endemic area for DENV, and CHIKV has always been detected in inexpressive numbers, being exclusively imported cases [10]. Nevertheless, in 2023, a significant increase in the number of CHIKV autochthonous cases was registered [11]. DENV and CHIKV co-circulation are challenging for health agencies, as they highlight the complexities of managing vector- borne diseases in endemic regions.

Here, we report two cases of simultaneous DENV and CHIKV infections, underscoring the importance of accurate differential diagnosis to manage coinfection symptoms and the viral genomic aspects.

Of the 533 evaluated samples from the 45th to 52nd epidemiological week of 2023, two cases were reported, showing a prevalence of 0.37%. During this period, the prevalence of dengue and CHIKV was 22.9% and 6.3%, respectively.

Case #1

A 77-year-old female patient had her plasma sample collected during the 47th epidemiological week of 2023. DENV-NS1 antigen immunoenzimatic assay (ELISA MARCA) and CHIKV-PCR (REF) were positive, with a cycle threshold (Ct) value of 18.6. The onset of the symptoms was November 18, 2023 (Day 1). No other positive cases were reported in the family.

Medical history: On Day 1, the patient presented with fever, myalgia, and severe arthralgia. On Day 3, laboratory tests for dengue revealed a positive NS1 ELISA and a non-detectable RT-PCR, while for Chikungunya, RT-PCR was detectable, and IgM-ELISA was reactive. The coinfection was confirmed through Dengue NS1 antigen and Real-Time PCR for CHIKV [12]. RT-PCR for DENV was negative.

Three days after the symptom’s onset, the patient sought medical attention, presenting with headache, myalgia, fever, arthralgia, and rash. Additionally, nausea and loss of appetite were reported, but no swelling was observed. The patient’s medical history included type 2 diabetes and arrhythmia, which made her part of a risk group for adverse outcomes. Furthermore, the initial blood count showed hemoconcentration following the upper reference limit for the age group (41 ± 6%) (Table 1).

Table 1: Blood count parameters and biochemical parameters.

Therefore, treatment with intravenous saline solution was immediately started, and she was closely monitored for signs of severe dengue. Joint pain and myalgia were relieved with analgesics (dipyrone and paracetamol) without the use of anti- inflammatories. Twenty-four days after symptoms onset, the patient experienced cervical pain radiating to the right shoulder, along with pain and swelling in the feet, which lasted for 15 days; swelling of the right wrist was also noted. Two months after the initial presentation, the patient was still suffering from persistent myalgia.

Despite the hemoconcentration typical of dengue, the blood count did not reveal thrombocytopenia. The white blood cell count was within normal limits but showed lymphopenia, which can be found in dengue and chikungunya infections. Liver enzymes were only slightly elevated, with AST levels higher than ALT levels, as commonly seen in dengue fever (Table 1). No significant changes were observed in biochemical parameters, such as urea, creatinine, sodium, and potassium.

Previous studies demonstrated that the elevation of aminotransferases can be attributed to the direct effect of the dengue virus on liver cells, as well as the immune response to the infection [13]. Significantly elevated levels of AST and ALT are often associated with more severe dengue manifestations and can serve as a marker for the severity of the infection [13].

Treatment and outcome: The patient’s clinical condition gradually improved over the following two weeks. Subsequently, she was discharged with instructions for adequate rest and scheduled for follow-up appointments to ensure continued recovery.

Case #2

A 12-year-old female patient sought medical attention, presenting fever, myalgia, back pain, and severe arthralgia. A plasma sample was collected on the 1st day of symptoms in the 48th epidemiological week of 2023. DENV and CHIKV RT- PCR were positive, showing a Ct of 36.9 and 24.8, respectively. DENV-NS1 antigen and CHIKV-IgM were both non-reactive. A family member was also positive for CHIKV. A complete blood count (Table 1) obtained on the 1st day of symptoms showed no hemoconcentration or thrombocytopenia. The white blood cell count was in the lower limit of normal with lymphopenia. Liver enzymes were normal. The patient also received supportive care to maintain hydration and alleviate joint pain. She was closely monitored for any complications, such as severe dengue. The patient’s clinical course, over the subsequent days following the presentation, included maintenance of arthralgia. No laboratory parameters were taken in the following period, as no clinical severity marker existed.

In this study, we outline two cases of simultaneous infection with DENV and CHIKV in Brazil, a new finding in a region previously undocumented for such coinfection. Despite the rarity of DENV-CHIKV coinfection discussions, most are from India, where the endemicity for both viruses is high, and a coinfected rate of 9.5% was reported [14-16].

The detection of DENV and CHIKV coinfections in December 2023, ahead of the anticipated epidemic season of April to June 2024, underscores an urgent need for the healthcare system to adapt to this evolving threat. This case was identified in the Ribeirão Preto region, with a significant history of dengue fever outbreaks, with annual confirmed cases reaching between 12,000 and 17,000 in recent years. Interestingly, according to the region’s health bulletin, CHIKV incidents belonging to imported origin have remained relatively low over the past five years (ranging from 0 to 8 cases per year) [11]. However, a notable increase in autochthonous cases was observed towards the end of 2023, November and December, the peak periods. This critical shift in the epidemiological landscape requires vigilant public health responses.

The spread of arboviruses is intricately linked to various factors, mainly climate factors such as rainy periods and extreme heat, which favor the proliferation of Aedes aegypti, the common vector for both DENV and CHIKV. Peculiarly, Aedes aegypti mosquitoes have been extensively studied, revealing that this mosquito species can harbor hosts and vectors for both viruses in vitro settings [16,17]. Lin and colleagues (2023) further demonstrated that simultaneous infection with DENV and Zika virus in Aedes aegypti could intensify viral replication within the mosquito [18]. This enhanced replication capacity, alongside the mosquito’s ability to transmit multiple viruses, raises critical questions regarding the potential for human infection resulting from successive exposures to mosquitoes carrying DENV, CHIKV, or both.

Considering the shared transmission vector for DENV and CHIKV, the dynamics of these coinfections among humans justify further investigation to understand the full scope of arbovirus transmission efficacy [19]. This case was detected in the areas where most CHIKV-confirmed cases were identified. The discrepancy between the results of serology and RT-PCR is explained. Early recognition and appropriate medical care are essential for a favorable patient outcome, although many clinical symptoms overlap between these viruses.

In case report #2, the positive CHIKV status of a family member may provide insights into potential sources of infection. Moreover, coinfection cases underscore the importance of diagnosing and managing coinfections, particularly in regions where DENV and CHIKV are cocirculating. Early recognition and appropriate medical care are essential for a favorable patient outcome, although many clinical symptoms overlap between these viruses.

The approval of the DENV vaccine, QDenga (Takeda, Japan), in March 2023, with the campaign launched in February 2024 focusing on specific age groups and priority regions, represents a significant advancement in dengue prevention. This vaccine is an attenuated virus with an efficacy of 72.7% [20]. However, one of the main critical challenges of managing dengue’s four serotypes is DENV-1, DENV-2, DENV-3, and DENV-4, once the infection with one serotype does not provide immunity against the others.

This challenge is exacerbated by the increasing number of autochthonous CHIKV cases in our region. Notably, CHIKV infection is already endemic in many other regions of Brazil, such as the Northeast, leading to coinfections that can complicate the diagnosis and management of patients due to overlapping clinical symptoms. Moreover, numerous questions remain unanswered regarding whether dual infection could result in more severe disease and complications. Additionally, the implementation of discriminatory diagnostics for DENV and CHIKV is currently lacking in Brazil’s public healthcare systems.

Our findings reinforce the critical need for comprehensive research into the dynamics of coinfection, immune responses, and the interactions between these viruses, aspects that remain insufficiently understood. There is a clear imperative need for robust surveillance systems, advanced diagnostic tools, effective vector management strategies, and public health education campaigns to mitigate the impact of these arboviral infections. Understanding and addressing the nuances of coinfection will be crucial in formulating effective responses to these public health challenges.

Consent for Publication

The case report has signed a consent for publication.

The authors declare that they have no financial and non- financial competing interests.

This study was supported by FAPESP through CTC (13/08135- 2) and CeVIVAS (21/11944-6), INCTC-CNPq (465539/2014-9);National Institutes of Health USA grant U01 AI151698 for the United World Arbovirus Research Network (UWARN) and the CRP-ICGEB RESEARCH GRANT 2020 Project CRP/BRA20-03, Contract CRP/20/03. M. Giovanetti’s funding is provided by PON “Ricerca e Innovazione’’ 2014-2020. D.G.L.L.R’s funding is provided by FAPESP 22/16349-1.

Methodology: DGLLR, LRP, LBMOC.

Patient Recruitment: PMAT, DBG, DCDG, LMRP. Clinical Management: BALF, FLSS.

Review and Editing: MG, VF, LCA, SK, DGLLR, MCE, VFMG, LMRP.

Data Curation: PMAT, SK, DGLLR, LMRP. Writing: SK and DGLLR.

Review and Editing: Conceptualization: SK and DGLLR.

Supervision and Funding Acquisition: SCS, RTC, DTC, LCA, and SK.

All individuals who participated agreed in this study.

This study was approved by the Institutional Ethics Committee of the Faculty of Medicine of Ribeirão Preto (Process CAAE: 59073722.0.0000.5440 registered at Plataforma Brasil).

1. Chen R, Mukhopadhyay S, Merits A, Bolling B, Nasar F, Coffey LL, et al. ICTV virus taxonomy profile: Togaviridae. Journal of General Virology. 2018; 99: 761-762.
2. Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. ICTV virus taxonomy profile: Flaviviridae. Journal of General Virology. 2017; 98: 2-3.
3. 3. Löwy I. Leaking containers: Success and failure in controlling the mosquito aedes aegypti in brazil. Am J Public Health. 2017; 107: 517- 524.
4. da Silva JB Jr, Siqueira JB Jr, Coelho GE, Vilarinhos PT, Pimenta FG Jr. Dengue in brazil: Current situation and prevention and control activities. Epidemiol Bull. 2002; 23: 3-6.
5. Rico-Hesse R. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology. 1990; 174: 479-493.
6. de Bruycker-Nogueira F, Mir D, dos Santos FB, Bello G. Evolutionary history and spatiotemporal dynamics of DENV-1 genotype V in the Americas. Infection, Genetics and Evolution. 2016; 45: 454-460.
7. Weaver SC, Forrester NL. Chikungunya: Evolutionary history and recent epidemic spread. Antiviral Res. 2015; 120: 32–39.
8. Ferreira de Almeida I, Codeço CT, Lana RM, Bastos LS, de Souza Oliveira S, Andreza da Cruz Ferreira D, et al. The expansion of chikungunya in Brazil. The Lancet Regional Health – Americas. 2023; 25: 100571.
9. Xavier J, Alcantara LCJ, Fonseca V, Lima M, Castro E, Fritsch H, et al. Increased interregional virus exchange and nucleotide diversity outline the expansion of chikungunya virus in Brazil. Nat Commun. 2023; 14: 4413.
10. de La-Roque DGL, Santos EV, Oliveira RAM, Slavov SN, Rodrigues ES, Fonseca V, et al. DENV-1 genotype V circulation during the nonepidemic period in the Northeast of São Paulo State endemic area. J Med Virol. 2024; 96: e29526.
11. Secretaria Municipal de Saúde de Ribeirão Preto. Departamento de Vigilância em Saúde (DEVISA). 2024.
12. Lanciotti RS, Kosoy OL, Laven JJ, Panella AJ, Velez JO, Lambert AJ, et al. Chikungunya virus in US travelers returning from India, 2006. Emerg Infect Dis. 2007; 13: 764–767.
13. Kalluru PKR, Mamilla M, Valisekka SS, Mandyam S, Calderon Martinez E, Posani S, et al. Aminotransferases in relation to the severity of dengue: A systematic review. Cureus. 2023; 15: e39436.
14. Kaur M, Singh K, Sidhu SK, Devi P, Kaur M, Soneja S, et al. Coinfection of chikungunya and dengue viruses: A serological study from North Western region of Punjab, India. J Lab Physicians. 2018; 10: 443–447.
15. Chahar HS, Bharaj P, Dar L, Guleria R, Kabra SK, Broor S. Co-infections with chikungunya virus and dengue virus in Delhi, India. Emerg Infect Dis. 2009; 15: 1077–1080.
16. Nuckols JT, Huang Y-JS, Higgs S, Miller AL, Pyles RB, Spratt Hm, et al. Evaluation of simultaneous transmission of chikungunya virus and dengue virus type 2 in infected aedes aegypti and aedes albopictus (Diptera: Culicidae). J Med Entomol. 2015; 52: 447–451.
17. Rückert C, Weger-Lucarelli J, Garcia-Luna SM, Young MC, Byas AD,Murrieta RA, et al. Impact of simultaneous exposure to arboviruses on infection and transmission by aedes aegypti mosquitoes. Nat Commun. 2017; 8: 15412.
18. Lin DC-D, Weng S-C, Tsao P-N, Chu JJH, Shiao S-H. Co-infection of dengue and zika viruses mutually enhances viral replication in the mosquito aedes aegypti. Parasit Vectors. 2023; 16: 160.
19. Jain J, Dubey SK, Shrinet J, Sunil S. Dengue chikungunya co-infection:A live-in relationship? Biochem Biophys Res Commun. 2017; 492: 608–616.
20. López-Medina, Biswal S, Saez-Llorens X, Borja-Tabora C, Bravo L, Sirivichayakul C, et al. Efficacy of a dengue vaccine candidate (TAK- 003) in healthy children and adolescents 2 years after vaccination. The Journal of Infectious Diseases. 2022; 225: 1521–1532